CA2340156A1 - .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b - Google Patents

.beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b Download PDF

Info

Publication number
CA2340156A1
CA2340156A1 CA002340156A CA2340156A CA2340156A1 CA 2340156 A1 CA2340156 A1 CA 2340156A1 CA 002340156 A CA002340156 A CA 002340156A CA 2340156 A CA2340156 A CA 2340156A CA 2340156 A1 CA2340156 A1 CA 2340156A1
Authority
CA
Canada
Prior art keywords
deoxy
beta
pentofuranonucleoside
erythro
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002340156A
Other languages
French (fr)
Other versions
CA2340156C (en
Inventor
Gilles Gosselin
Jean-Louis Imbach
Martin L. Bryant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Centre National de la Recherche Scientifique CNRS
Universite Montpellier 2 Sciences et Techniques
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26791121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2340156(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to CA002599597A priority Critical patent/CA2599597A1/en
Publication of CA2340156A1 publication Critical patent/CA2340156A1/en
Application granted granted Critical
Publication of CA2340156C publication Critical patent/CA2340156C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-.alpha.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside has formula (I) wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2'-deoxy-.beta.-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
CA002340156A 1998-08-10 1999-08-10 .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b Expired - Lifetime CA2340156C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002599597A CA2599597A1 (en) 1998-08-10 1999-08-10 .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9611098P 1998-08-10 1998-08-10
US60/096,110 1998-08-10
US13135299P 1999-04-28 1999-04-28
US60/131,352 1999-04-28
PCT/US1999/018149 WO2000009531A2 (en) 1998-08-10 1999-08-10 β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002599597A Division CA2599597A1 (en) 1998-08-10 1999-08-10 .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b

Publications (2)

Publication Number Publication Date
CA2340156A1 true CA2340156A1 (en) 2000-02-24
CA2340156C CA2340156C (en) 2007-10-23

Family

ID=26791121

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002340156A Expired - Lifetime CA2340156C (en) 1998-08-10 1999-08-10 .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b

Country Status (22)

Country Link
US (5) US6395716B1 (en)
EP (2) EP2415776B1 (en)
JP (2) JP4294870B2 (en)
KR (4) KR100634342B1 (en)
CN (3) CN1257912C (en)
AT (1) ATE313550T1 (en)
AU (1) AU5475799A (en)
BR (1) BRPI9912896B8 (en)
CA (1) CA2340156C (en)
CY (2) CY2007017I1 (en)
DE (2) DE69929060T2 (en)
DK (3) DK2415776T3 (en)
ES (3) ES2531928T3 (en)
FR (1) FR07C0046I2 (en)
HK (3) HK1034083A1 (en)
LU (1) LU91348I2 (en)
MX (1) MXPA01001507A (en)
NL (1) NL300286I2 (en)
PT (2) PT2415776T (en)
RU (1) RU2424016C2 (en)
SG (1) SG132498A1 (en)
WO (1) WO2000009531A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT831852E (en) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleosides with anti-hepatitis b virus activity
WO2000009531A2 (en) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
TR200601783T2 (en) * 1999-11-12 2007-01-22 Pharmasset Ltd Synthesis of 2'-Deoxy-L-nucleosides
BRPI0108435B8 (en) * 2000-02-29 2021-05-25 Bristol Myers Squibb Co formulation and use of low-dose entecavir
WO2001067772A2 (en) * 2000-03-09 2001-09-13 Videoshare, Inc. Sharing a streaming video
US6822089B1 (en) * 2000-03-29 2004-11-23 Isis Pharmaceuticals, Inc. Preparation of deoxynucleosides
BR0110023A (en) 2000-04-13 2003-12-30 Pharmasset Ltd Substituted 3'-or-2 'nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
TR200402565T4 (en) 2000-05-26 2004-12-21 Idenix (Cayman) Limited Use of ß-L-2'-deoxy-nucleosides in the treatment of hepatitis delta virus infection
EP1294735A2 (en) 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CN101250208B (en) * 2000-11-29 2012-06-20 三井化学株式会社 L-nucleic acid derivative and processes for the synthesis thereof
JP3942414B2 (en) 2000-11-29 2007-07-11 三井化学株式会社 L-type nucleic acid derivative and synthesis method thereof
WO2003053360A2 (en) 2001-12-20 2003-07-03 Pharmassett Ltd. Treatment of ebv and khsv infection and associated abnormal cellular proliferation
JP2005514401A (en) * 2001-12-21 2005-05-19 マイクロロジックス　バイオテック，インコーポレイテッド Antiviral 7-deaza L-nucleoside
AU2003217863B9 (en) * 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
DE60303131T2 (en) * 2002-06-27 2006-07-20 Medivir Ab SYNERGISTIC INTERACTION OF ABACAVIR AND ALOVUDIN
MXPA04012779A (en) 2002-06-28 2005-08-19 Idenix Cayman Ltd 2' and 3'-nucleoside prodrugs for treating flaviviridae infections.
KR20050035194A (en) * 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN101172993A (en) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
RS114004A (en) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
AU2003278816A1 (en) * 2002-09-13 2004-04-30 Idenix (Cayman) Limited ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
ATE442375T1 (en) 2002-10-31 2009-09-15 Metabasis Therapeutics Inc CYTARABINE MONOPHOSPHATE PRODRUGS
CN1849142A (en) * 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2'-branched nucleosides and flaviviridae mutation
US7598373B2 (en) * 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
EP1745573A4 (en) 2003-03-20 2010-05-26 Microbiol Quimica Farmaceutica Methods of manufacture of 2 -deoxy- beta-l-nucleosides
CN1812995A (en) * 2003-04-28 2006-08-02 艾登尼科斯（开曼）有限公司 Industrially scalable nucleoside synthesis
WO2004096197A2 (en) * 2003-05-02 2004-11-11 Universita Degli Studi Di Cagliari 5-aza-7-deazapurine nucleosides for treating flaviviridae
EP2345661A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
WO2005003374A2 (en) 2003-06-30 2005-01-13 Idenix (Cayman) Limited SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES
CN1315863C (en) * 2003-12-12 2007-05-16 河南省科学院质量检验与分析测试研究中心 Beta-2'-deoxygenation-ramification of nucleotide, synthetic method and application of medication
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Pharmasset Llc Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (en) * 2005-03-11 2010-08-04 株式会社ケンウッド Speech synthesis apparatus, speech synthesis method and program
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
EP1976382B1 (en) * 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
CN101466727B (en) 2006-04-11 2012-10-17 诺瓦提斯公司 Hcv/hiv inhibitor and their uses
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090082306A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telbivudine
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
AR074897A1 (en) 2008-12-23 2011-02-23 Pharmasset Inc NUCLEOSID PHOSPHORAMIDATES
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
JP5779799B2 (en) * 2009-11-16 2015-09-16 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド 2'-Fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
EP2752422B1 (en) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
ES2716158T3 (en) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleotides for the treatment of hepatitis C
CN102649788B (en) * 2011-02-28 2015-03-25 四川大学 Beta-L-2'-desoxy-thymin-nucleoside derivative, preparation method and purposes thereof
MD4589C1 (en) 2011-09-16 2019-03-31 Gilead Pharmasset Llc Pharmaceutical composition comprising sofosbuvir and uses thereof for treating hepatitis C virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NZ625087A (en) 2013-01-31 2017-05-26 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
ES2900570T3 (en) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
JP2017520545A (en) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド Prodrug compounds and their use
CN110680806A (en) * 2018-07-04 2020-01-14 郑州泰丰制药有限公司 Preparation method of telbivudine particles
CN108570078A (en) * 2018-07-18 2018-09-25 荆门医药工业技术研究院 A method of preparing three-O- benzoyls-β of 1-O- acetyl group -2,3,5--D-RIBOSE
CN114133398B (en) * 2021-12-31 2022-11-22 中南民族大学 Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB875971A (en) 1959-01-14 1961-08-30 Hoffmann La Roche A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4916122A (en) 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
AU2526188A (en) 1987-09-22 1989-04-18 Regents Of The University Of California, The Liposomal nucleoside analogues for treating aids
CA1329932C (en) 1987-10-28 1994-05-31 Reid Von Borstel Acyl deoxyribonucleoside derivatives and uses thereof
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
JP2675864B2 (en) 1988-07-05 1997-11-12 キヤノン株式会社 Recording material and inkjet recording method using the same
SE8802687D0 (en) 1988-07-20 1988-07-20 Astra Ab NUCLEOSIDE DERIVATIVES
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
WO1992001138A1 (en) 1990-07-12 1992-01-23 G-Drill Ab Hydraulic down-the-hole rock drill
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
IT1246983B (en) 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-DESOXYURIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int Pharmaceutical compositions containing cis-4-amino-1(hydroxymethyl-1,3-oxathiolan-5-yl)-1H-pyrimid-2-one nucleoside or its derivatives
DE69233693T2 (en) 1991-03-06 2008-01-24 Emory University Salts and amides of (-) cis 5-fluoro-2'-deoxy-3'-thiacytidine suitable for the treatment of hepatitis B
US5220003A (en) 1991-03-29 1993-06-15 The Regents Of The University Of California Process for the synthesis of 2',3'-dideoxynucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
AU6402594A (en) * 1993-03-10 1994-09-26 Wellcome Foundation Limited, The Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
JP3693357B2 (en) 1993-04-09 2005-09-07 峯郎 実吉 Reverse transcriptase inhibitor
WO1994026273A1 (en) 1993-05-12 1994-11-24 Hostetler Karl Y Acyclovir derivatives for topical use
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
CA2637774C (en) 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996011204A1 (en) * 1994-10-07 1996-04-18 Max-Delbrück-Centrum für Molekulare Medizin NOVEL β-L-NUCLEOSIDES AND THEIR USE
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
PT831852E (en) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleosides with anti-hepatitis b virus activity
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
WO1999045935A1 (en) 1998-03-11 1999-09-16 Lipitek International, Inc. Novel nucleoside analogs and uses in treating disease
AU4716299A (en) 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
WO2000009531A2 (en) * 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1294735A2 (en) * 2000-05-26 2003-03-26 Novirio Pharmaceuticals Limited Methods and compositions for treating flaviviruses and pestiviruses
TR200402565T4 (en) * 2000-05-26 2004-12-21 Idenix (Cayman) Limited Use of ß-L-2'-deoxy-nucleosides in the treatment of hepatitis delta virus infection
US6787526B1 (en) * 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides

Also Published As

Publication number Publication date
CN1606983A (en) 2005-04-20
DE69929060D1 (en) 2006-01-26
KR100702230B1 (en) 2007-04-03
PT2415776T (en) 2016-07-07
FR07C0046I2 (en) 2008-05-09
ES2531928T3 (en) 2015-03-20
KR20060038483A (en) 2006-05-03
ES2579903T3 (en) 2016-08-17
US6395716B1 (en) 2002-05-28
CN1257912C (en) 2006-05-31
CY1116988T1 (en) 2017-04-05
BRPI9912896B8 (en) 2021-05-25
CN1320128A (en) 2001-10-31
BRPI9912896B1 (en) 2016-08-09
CN1478483A (en) 2004-03-03
US20030225028A1 (en) 2003-12-04
JP2007269798A (en) 2007-10-18
HK1097776A1 (en) 2007-07-06
ATE313550T1 (en) 2006-01-15
RU2424016C2 (en) 2011-07-20
US20080064655A1 (en) 2008-03-13
BR9912896A (en) 2002-02-13
JP2002522552A (en) 2002-07-23
DK2415776T3 (en) 2016-07-04
EP1104436B1 (en) 2005-12-21
PT1431304E (en) 2015-03-09
AU5475799A (en) 2000-03-06
LU91348I2 (en) 2007-09-18
CY2007017I2 (en) 2009-11-04
NL300286I1 (en) 2007-10-01
EP1104436A2 (en) 2001-06-06
CN100482236C (en) 2009-04-29
KR100568035B1 (en) 2006-04-07
DK1104436T3 (en) 2006-04-03
KR20050062664A (en) 2005-06-23
RU2006147216A (en) 2008-07-10
ES2255295T3 (en) 2006-06-16
NL300286I2 (en) 2008-01-02
CY2007017I1 (en) 2009-11-04
SG132498A1 (en) 2007-06-28
DK1431304T3 (en) 2015-03-02
WO2000009531A3 (en) 2000-06-15
CA2340156C (en) 2007-10-23
EP2415776B1 (en) 2016-05-25
JP4294870B2 (en) 2009-07-15
CN100387237C (en) 2008-05-14
KR20060035817A (en) 2006-04-26
MXPA01001507A (en) 2003-09-10
LU91348I9 (en) 2018-12-31
KR100691737B1 (en) 2007-03-12
EP2415776A1 (en) 2012-02-08
US6569837B1 (en) 2003-05-27
US7304043B2 (en) 2007-12-04
US20060084624A1 (en) 2006-04-20
KR100634342B1 (en) 2006-10-16
HK1034083A1 (en) 2001-10-12
WO2000009531A2 (en) 2000-02-24
KR20010072392A (en) 2001-07-31
HK1111913A1 (en) 2008-08-22
FR07C0046I1 (en) 2007-10-26
DE69929060T2 (en) 2006-08-31
DE122007000062I1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
CA2340156A1 (en) .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
JP2004513070A5 (en)
AR035711A1 (en) PRODROGAS 3 'DE 2'-DEOXI-BETA-L-NUCLEOSIDOS; YOUR PHARMACEUTICAL COMPOSITIONS; METHOD FOR THE TREATMENT OR PROFILAXIS OF AN INFECTION OF THE HEPATITIS B VIRUS AND ITS USES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
CA2389745A1 (en) Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
KR870006900A (en) Antiviral composition
DE69031340T2 (en) ANTIVIRAL COMPOSITIONS CONTAINING 3'-AZIDO-2 ', 3'-DIDEOXY-5-METHYLCYTIDINE
HK1036069A1 (en) Nucleosides with anti-hepatitis b virus activity
HU901252D0 (en) Process for manufacturing of pharmaceutical compositions comprising purine derivatives
CY1117836T1 (en) BETA-L-2'-DEOXY-NUCLEOSIDES FOR USE TREATMENT B
RU2001106651A (en) BETA-L-2 - DESOXY-NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS IN
HUT52110A (en) Process for producing compounds with antiviral effect and pharmaceutical compositions comprising same
IL142982A0 (en) β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION
CY2338B1 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections.
MX9704336A (en) Use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpesvirus infections.
CA2538205A1 (en) Nucleosides with anti-hepatitis b virus activity

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190812